23andMe, Genentech Recruiting Patients for Alzheimer's Genetics Research
June 29, 2011
23andMe, Genentech Recruiting Patients for Alzheimer's Genetics Research
"This research could lead to new scientific knowledge or possibly a drug that could prevent or slow [the] disease," 23andMe states in an informational release targeted to customers who may be eligible to participate in an Alzheimer's study it is conducting with biotech partner Genentech.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- 23andMe, Genentech Expand Study Targeting Avastin
January 29, 2013 / GenomeWeb Daily News - With Decode Purchase, Amgen Gains Genetics Expertise, Consumers Lose DTC Testing Option
December 12, 2012 / Pharmacogenomics Reporter - Seeking 510(k) Clearance for Genomic Testing Service, 23andMe Maintains Direct-to-Consumer Ethos
August 1, 2012 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter